Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News IO Biotech Inc IOBT

Healthcare Biotechnology
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company’s lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death... see more

Current News (NDAQ:IOBT)

IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications

GlobeNewswire December 15, 2025

IO Biotech Announces Participation in Upcoming December Investor Conferences

GlobeNewswire November 26, 2025

IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights

GlobeNewswire November 14, 2025

IO Biotech Announces Participation in Upcoming Investor Conferences

GlobeNewswire November 12, 2025

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewswire November 7, 2025

IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

GlobeNewswire October 20, 2025

IO Biotech Provides Update Following Pre-BLA Meeting with FDA

GlobeNewswire September 29, 2025

IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025

GlobeNewswire September 23, 2025

IO Biotech Announces Participation in Upcoming Investor Conferences

GlobeNewswire September 4, 2025
View More News ››

Opinion & Analysis (NDAQ:IOBT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:IOBT)

Be the first to post on this bullboard.

Eshbal Functional Food Inc

Eshbal Functional Food Inc

Eshbal Functional Food Inc. researches, develops, and manufactures food products and dietary supplements Israel, North ...
View More »

Podcasts